Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Abstract

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

Keywords

• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Drug toxicity
• Drug interactions
• Gastrointestinal tract
• Drug resistance, neoplasm
• Pyrimidines
• Interferonalpha
• Piperazines
• Clinical Trial